David Calhoun to Angiotensin-Converting Enzyme Inhibitors
This is a "connection" page, showing publications David Calhoun has written about Angiotensin-Converting Enzyme Inhibitors.
Connection Strength
0.428
-
Nishizaka MK, Zaman MA, Calhoun DA. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens. 2003 Nov; 16(11 Pt 1):925-30.
Score: 0.204
-
Pimenta E, Calhoun DA. Resistant hypertension and aldosteronism. Curr Hypertens Rep. 2007 Nov; 9(5):353-9.
Score: 0.067
-
Calhoun DA. Low-dose aldosterone blockade as a new treatment paradigm for controlling resistant hypertension. J Clin Hypertens (Greenwich). 2007 Jan; 9(1 Suppl 1):19-24.
Score: 0.064
-
Zaman MA, Oparil S, Calhoun DA. Drugs targeting the renin-angiotensin-aldosterone system. Nat Rev Drug Discov. 2002 Aug; 1(8):621-36.
Score: 0.047
-
Matanes F, Khan MB, Siddiqui M, Dudenbostel T, Calhoun D, Oparil S. An Update on Refractory Hypertension. Curr Hypertens Rep. 2022 07; 24(7):225-234.
Score: 0.046